Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI× anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for …
HH Van Ojik, R Repp, G Groenewegen… - Cancer Immunology …, 1997 - search.proquest.com
HH Van Ojik, R Repp, G Groenewegen, T Valerius, JGJ van de Winkel
Cancer Immunology, Immunotherapy, 1997•search.proquest.comBreast cancer represents a major public health problem, afflicting 12% of women in affluent
countries [7]. Although considerable cure rates are achieved in localized disease, the results
in advanced disease are still disappointing [8]. Therefore new therapeutic strategies are
warranted. In the last decade, along with new chemotherapeutic drugs, developments in the
field of immunotherapy have opened up new perspectives [2, 12]. Here we describe a novel
immunotherapeutic approach, and present preliminary results from an ongoing phase I trial.
countries [7]. Although considerable cure rates are achieved in localized disease, the results
in advanced disease are still disappointing [8]. Therefore new therapeutic strategies are
warranted. In the last decade, along with new chemotherapeutic drugs, developments in the
field of immunotherapy have opened up new perspectives [2, 12]. Here we describe a novel
immunotherapeutic approach, and present preliminary results from an ongoing phase I trial.
Breast cancer represents a major public health problem, afflicting 12% of women in affluent countries [7]. Although considerable cure rates are achieved in localized disease, the results in advanced disease are still disappointing [8]. Therefore new therapeutic strategies are warranted. In the last decade, along with new chemotherapeutic drugs, developments in the field of immunotherapy have opened up new perspectives [2, 12]. Here we describe a novel immunotherapeutic approach, and present preliminary results from an ongoing phase I trial.
ProQuest